MYFEMBREE 40 MG-1 MG-0.5 MG TB

relugolix, estradiol hemihydrate, and norethindrone acetate
$45.3620per EA

Strength

1; .5; 40 mg/1; mg/1; mg/1

NDC

72974041501

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

12/30/2025

Approval Type

New Drug (NDA)

FDA Application

NDA214846

On Market Since

5/26/2021

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Cytochrome P450 2B6 Inducers
Cytochrome P450 3A Inducers
Decreased GnRH Secretion
Estradiol Congeners
Estrogen Receptor Agonists
Estrogen
Gonadotropin Releasing Hormone Receptor Antagonist
Gonadotropin Releasing Hormone Receptor Antagonists
P-Glycoprotein Inhibitors
Progesterone Congeners
Progestin

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+6.0%

1Y

+5.8%

3Y

+21.1%

5Y

N/A

All

+27.2%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.